Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia

Background: Schizophrenia causes significant neurocognitive impairment. Treatment with antipsychotics leads to improvement in psychopathology and neurocognitive functions. Aim: To see comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. M...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sanya Sharma, Ajeet Sidana, Shivangi Mehta, Manoj Kumar Bajaj
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-10-01
Series:	Indian Journal of Psychiatry
Subjects:	aripiprazole neurocognitive functions olanzapine schizophrenia
Online Access:	https://journals.lww.com/10.4103/indianjpsychiatry.indianjpsychiatry_303_23
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment
by: JiaHui Zeng, et al.
Published: (2025-01-01)

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
by: Zhen Mao, et al.
Published: (2024-12-01)

Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study
by: Yi-Ting Yeh, et al.
Published: (2025-07-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-10-01)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
by: Kishi T, et al.
Published: (2016-11-01)

A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia
by: Tianbao Wei, et al.
Published: (2025-01-01)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
by: Peters-Strickland T, et al.
Published: (2016-10-01)

Olanzapine-induced Pancytopenia: Case Report
by: A Prajnashree, et al.
Published: (2024-11-01)

Modern dilemma in the therapy of the schizophrenia: neurocognition and social cognition
by: N. B. Lutova, et al.
Published: (2019-10-01)

Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
by: Yin Cao, et al.
Published: (2024-12-01)

Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2020-10-01)

Comparative study: trimetazidine versus olanzapine on cognitive dysfunction and behavioral changes in ketamine-induced psychosis model in mice
by: Yosra Magdy, et al.
Published: (2025-04-01)

Approaches to evaluation of neurocognitive profile in patients with residual schizophrenia depending on a history of cerebral stroke
by: D. M. Safonov, et al.
Published: (2024-10-01)

Antipsychotic medication for behaviors that challenge in individuals with intellectual disabilities: a clinically informed review
by: Alessandro Pascucci, et al.
Published: (2025-07-01)

Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
by: A. R. Asadullin, et al.
Published: (2025-06-01)

Neurocognitive dysfunctions in childhood-onset schizophrenia: A systematic review
by: A. Armita, et al.
Published: (2025-06-01)

Membrane Permeability Monitoring to Antipsychotic Olanzapine Using Platinum Black-Modified Electrodes
by: Murugaiya Sridar Ilango, et al.
Published: (2025-04-01)

One-Year Course of Olanzapine-Induced Diabetic Ketoacidosis: A Case Report
by: Mohammed Zain Ulabedin Adhoni, et al.
Published: (2021-10-01)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
by: Anand E, et al.
Published: (2016-10-01)

Prevalence of neurocognitive deficits in patients with first-episode schizophrenia in an African sample and its relationship with dimensions of psychopathology and psychosocial outcome
by: Onyekachi Kingsley Ugwuonye, et al.
Published: (2024-12-01)

Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps
by: A. N. Kornetov, et al.
Published: (2019-08-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01)

Otizm ve tourette sendromu birlikteliğinde düşük doz aripiprazol monoterapisinin etkinliği: olgu sunumu
by: Necati Uzun
Published: (2018-01-01)

Olanzapine-induced neutropenia
by: Kirti Malhotra, et al.
Published: (2015-06-01)

The brain-gut microbiota network (BGMN) is correlated with symptom severity and neurocognition in patients with schizophrenia
by: Runlin Peng, et al.
Published: (2025-03-01)

Ketamine and olanzapine alter behaviour and prefrontal-cortex BDNF differentially in male and female rats
by: Kalin Manooki, et al.
Published: (2025-08-01)

Unusual Weight Loss in a Schizophrenic Patient Following Treatment With Aripiprazole: A Case Report
by: Amir Asadi, et al.
Published: (2025-03-01)

Clinical Effectiveness of Aripiprazole in Short-term Treatment of Tic Disorder in Children and Adolescents: A Naturalistic Study
by: Che-Sheng Ho, et al.
Published: (2014-02-01)

METHODS ELABORATION ON DETECTION OF SOME ATYPICAL NEUROLYTIC AGENTS FOR CHEMICAL AND TOXICOLOGICAL ANALYSIS
by: I. P. Remezova, et al.
Published: (2015-09-01)

Agar/β-Cyclodextrin Composite Cryogels for Controlled Release of Aripiprazole
by: Siyka Stoilova, et al.
Published: (2025-02-01)

Exploring the efficacy and tolerability of two‐injection start regimen of long‐acting aripiprazole: A descriptive case series analysis
by: Ibrahim Sungur, et al.
Published: (2024-12-01)

Reduction Behavior of Olanzapine and Its Differential Pulse Voltammetric Determination in Human Urine and Pharmaceuticals
by: Sultan Yağmur
Published: (2020-12-01)

An Approach to Enhance the Solubility of an Atypical Antipsychotic Drug, Aripiprazole: Design, Characterization, and Evaluation of Arabinoxylan-Based Nanoparticles
by: Sikander M, et al.
Published: (2025-02-01)

Evaluation of the combined effect of aripiprazole and sertraline in the treatment of obsessive-compulsive disorder in adolescents
by: Fatemeh Assarian, et al.
Published: (2024-12-01)

Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
by: Bilal Kazi, et al.
Published: (2025-03-01)

Olanzapine: The game-changer “antiemetic”
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Low-dose aripiprazole for refractory burning mouth syndrome
by: Umezaki Y, et al.
Published: (2016-05-01)

Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function
by: Qi Zhou, et al.
Published: (2025-07-01)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
by: Shi C, et al.
Published: (2016-08-01)